AzTrials
AzTrials

Heart FailureSMILE™NCT02448342

Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients

A study testing Remote Dielectric Sensing (ReDS) Wearable System in people with Heart Failure, run by Sensible Medical Innovations Ltd. at 41 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Multi center, randomized controlled study, to determine if a significant decrease in the rate of heart failure re-hospitalizations occurs during a follow-up period when - ReDS guided treatment is used as an adjunct to standard of care. Read more about this study

Who is it for?
Ages 21 years and older
Conditions the study is for
Heart Failure
What is being tested?
Remote Dielectric Sensing (ReDS) Wearable System
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
380 participants
Where
41 sitesUnited States
Study dates
Sep 2015to 30 Nov 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Main Inclusion Criteria:

  1. Patient has signed informed consent and authorization to use and disclose health information.
  2. Patient's physical condition enables him to sit up and lay down with minimal assistance.
  3. Diagnosis of HF, with preserved or reduced LVEF, was made at least 30 days prior to enrollment.
  4. Patients with LVEF <40% must have been treated at least 30 days prior to enrollment with diuretics and beta-blocker (unless intolerant or contra-indicated) and an ACE-inhibitor or ARB (unless intolerant or contra-indicated).
  5. Patient is hospitalized for ADHF requiring significant alteration in heart failure treatment (i.e. diuretics or vasoactive drugs) or up to 10 days post-discharge from an ADHF admission.
  6. BNP ≥ 350 pg/ml (NT pro BNP > 1400 pg/ml) at enrollment (within 24h) and/or ≥750 pg/ml any time during the hospital stay (NT-pro BNP >3000 pg/ml).

Note that if a patient is enrolled during a clinic visit rather than during a hospitalization, then the BNP from the index admission is referenced.

Main Exclusion Criteria:

  1. Patient has had a cardiac transplantation or VAD implantation.
  2. CRT implantation within 90 days prior to screening or planned implantation during study duration.
  3. Current or past Pulmonary Embolism in the right lung. Notes: (i) Past pulmonary emboli are defined as identified <6 months prior to enrollment. (ii) past or current tiny, microscopic pulmonary emboli do not exclude a patient. (iii) if a ventilation-perfusion (VQ) scan shows that the lungs are clear, then the exclusion criteria is not met.
  4. Diagnosis of Severe Pulmonary Hypertension.
  5. STEMI and or CABG within 30 days of screening visit. Note: Type 2 MI due to ADHF is not an exclusion.
  6. Chronic renal failure with CrCl<25mL/min, as calculated by the Cockcroft-Gault formula.
  7. Chronic home IV therapy or cardiac inotropes or diuretics
  8. Physical deformity in the thorax area or lesion that may prevent proper vest application or adjustment (Severe scoliosis/ sensitive sternotomy lesion etc.).
  9. Illness/ Condition which may be aggravated or cause significant discomfort by the application of the vest (Rib fractures, with or without flail chest, Severe Osteoporosis).
  10. Impaired cognitive ability or any other state that may prevent full compliance with the study protocol, according to investigator's assessment.
  11. Patient's habitus out of range due to one or more of the following:
  • Height less than 155cm or higher than 195cm (5.1; 6.4 feet respectively).
  • BMI of less than 22 or more than 36. In case of BMI between 36-38, if the measured vest ruler is not >=4, the exclusion criteria is met.
  1. Congenital heart malformations or intra-thoracic mass that would affect the right lung anatomy (Dextrocardia, Lung Carcinoma etc.) including pacemaker box on the right side of the chest.
  2. Severe COPD, defined as chronic and continuous home use of O2 (O2 dependancy) and/ or oral steroids. Continuous is defined as 24hours a day, every day.
  3. Severe disease / conditions with life expectancy <6 months according to investigator's assessment.
  4. Patient is enrolled in another interventional study with permission of study manager (observational or registries are not excluded).
  5. Patient HF is managed remotely with another monitoring device or program (for example: Pulmonary/ Lt Atrial pressure monitoring, Weight scale, BNP or bioimpedance).
  6. Prisoners and ward of the state

Trial locations and contacts

41 sites in 1 country.

41 sites in 1 country

United States41 sites
  • Suma Health Services

    Akron, Ohio, 44304

  • Piedmont Heart Institute

    Atlanta, Georgia, 30309

  • University of Alabama

    Birmingham, Alabama, 35294-0007

  • University of Chicago

    Chicago, Illinois, 60637

  • Cleveland Clinic

    Cleveland, Ohio, 44195

  • Dorothy M. Davis Heart & Lung Research Institute at The Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210-1252

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210-1252

  • Geisinger Medical Center

    Danville, Pennsylvania, 17822

  • St Elizabeth Healthcare

    Edgewood, Kentucky, 41017

  • Elmhurst Memorial Hospital

    Elmhurst, Illinois, 60126

  • Northshore University HealthSystem

    Evanston, Illinois, 60201

  • Advanced Heart Care Group

    Fairview Heights, Illinois, 62208

  • Cedars Sinai

    Hollywood, California, 90048

  • Memorial Regional Hospital

    Hollywood, Florida, 33021

  • Encore Research Group

    Jacksonville, Florida, 32207

  • Saint Luke's Hospital of Kansas City

    Kansas City, Missouri, 64111

  • Scripps Memorial Hospital La Jolla

    La Jolla, California, 92037

  • Lancaster General Health Hospital

    Lancaster, Pennsylvania, 17603

  • Bryan Heart

    Lincoln, Nebraska, 68506

  • North Shore University Hospital

    Manhasset, New York, 11030

  • Virginia Cardiovascular Specialties

    Midlothian, Virginia, 23112

  • Minneapolis Heart Institute Foundation

    Minneapolis, Minnesota, 55407

  • Edward Heart Hospital

    Naperville, Illinois, 60540

  • Centennial Medical Center - Sarah Cannon Research Institute

    Nashville, Tennessee, 37203

  • Yale University Medical Center

    New Haven, Connecticut, 06519

  • Long Island Jewish Hospital

    New Hyde Park, New York, 11040

  • Mount Sinai Medical Center

    New York, New York, 10029

  • Weil Cornell Medical Center

    New York, New York, 10065

  • Lenox Hill Hospital

    New York, New York, 10075

  • Drexel University Medical Center

    Philadelphia, Pennsylvania, 19102

  • VA Pittsburgh Health System

    Pittsburgh, Pennsylvania, 15240

  • Henrico Doctors' Hospital

    Richmond, Virginia, 23229

  • Scripps Mercy Hospital San Diego

    San Diego, California, 92103

  • UCSF Medical Center, Parnassus

    San Francisco, California, 94143

  • Pacific Heart Institute

    Santa Monica, California, 90404

  • Prairie Heart Institute / St. John's Hospital

    Springfield, Illinois, 62701

  • St. Louis Heart and Vascular

    St Louis, Missouri, 63136

  • MedStar Heart and Vascular Institute

    Washington D.C., District of Columbia, 20010

  • Washington DC VA Medical Center

    Washington D.C., District of Columbia, 20422

  • Geisinger Wyoming Valley Medical Center

    Wilkes-Barre, Pennsylvania, 17822

  • Pinnacle Health Cardiovascular Institute

    Wormleysburg, Pennsylvania, 17043

Other trials in United States

About this study

Official title: Sensible Medical Innovations (Noninvasive) Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients- a Randomized Controlled Study

Multi center, randomized controlled study, to determine if a significant decrease in the rate of heart failure re-hospitalizations occurs during a follow-up period when - ReDS guided treatment is used as an adjunct to standard of care.

Read the detailed description

The study is designed as a prospective, randomized, controlled, multi-center trial. Patients will be enrolled during an index hospitalization for Acutely decompensated Heart Failure (ADHF) and will be followed for a minimum of 3 months or a maximum of 9 months (until the last patient has completed the 3- month follow-up). Patients will be blinded to ReDS readings values.

Recruitment will take place either during a heart failure hospitalization (see acceptance criteria below) or within 10 days after discharge from a qualifying heart failure hospitalization.

The Remote Dielectric Sensing (ReDS) device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.

Study objective is to determine if a significant decrease in the rate of heart failure re-hospitalizations occurs during the entire follow-up period when ReDS guided treatment is used as an adjunct to standard of care (SOC).

Patients will be randomized between two groups before hospital discharge to: ReDS with SOC vs. SOC.

Patient that are randomized to the treatment arm will perform daily ReDS measurement at home. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines.

Patients that are randomized to the control arm will be followed up and medically managed according to standard of care guidelines.

Both arms scheduled clinical visits and phone follow up:

  • A follow up phone call, per current treatment guidelines, will be attempted within 2 days of hospital discharge to obtain information regarding medication reconciliation, Heart Failure (HF) symptoms and other HF management issues (e.g., dietary restrictions).
  • An outpatient clinic visit will be scheduled after a week of hospital discharge.
  • Study follow-up visits at 1 and 3 months. Follow-up will be continued for enrolled subjects at 6 and 9 months until the last subject has pass through the 3-month follow-up window.
  • At each study follow-up visit, patients will undergo complete physical exam, vital signs, collection of readmission and standard blood tests and QOL questionnaire.
Conditions
Heart Failure
Being tested
Remote Dielectric Sensing (ReDS) Wearable System
Keywords
Heart Failure, Remote Patient Monitoring, Non Invasive Lung Fluid Status Monitor
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Remote Dielectric Sensing (ReDS) Wearable SystemDevice

    Also called ReDS, Wearable Vest

    The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.

Study groups in NCT02448342
Study groupRoleWhat they receive
ReDS Guided TreatmentExperimentalAfter discharge from hospital, patient will perform daily ReDS measurement. Data is automatically transmitted to the secured web portal. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines. During the study a service center will monitor and support patient adherence and investigators attending to patients' notifications.
Receives: Device: Remote Dielectric Sensing (ReDS) Wearable System
Standard of Care- Control armActive comparatorAfter discharge from hospital, patient will be followed up and medically managed according to standard of care guidelines.
Receives: Device: Remote Dielectric Sensing (ReDS) Wearable System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The rate of recurrent events of HF readmissions

    Measured: Entire follow-up period (Expected average of 6.5 months)

Secondary outcomes (3)
  1. Time from discharge until the first event of HF readmissions

    Measured: Time to event (from discharge until the date of first event of HF readmissions, assessed up to 6.5 months)

  2. Proportions of total days lost to hospitalization due to HF events

    Measured: Entire follow-up period (Expected average of 6.5 months)

  3. Time from discharge until all-cause mortality

    Measured: time to event (from time of discharge until the date of first event of HF readmissions, assessed up to 6.5 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 May 2015 (estimated)
  2. Study startSep 2015
  3. Primary completion30 Nov 2017
  4. Study completion30 Nov 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
380 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02448342
Sponsor's protocol ID
CL-00100-P
Acronym
SMILE™
Status last verified
Aug 2017
First submitted
10 May 2015
Last updated
29 Dec 2017
Results posted
No
Data monitoring committee
Yes

Publications

  • Amir O, Rappaport D, Zafrir B, Abraham WT. A novel approach to monitoring pulmonary congestion in heart failure: initial animal and clinical experiences using remote dielectric sensing technology. Congest Heart Fail. 2013 May-Jun;19(3):149-55. doi: 10.1111/chf.12021. Epub 2013 Jan 25.

    PubMed 23350643
  • Amir O, Azzam ZS, Gaspar T, Faranesh-Abboud S, Andria N, Burkhoff D, Abbo A, Abraham WT. Validation of remote dielectric sensing (ReDS) technology for quantification of lung fluid status: Comparison to high resolution chest computed tomography in patients with and without acute heart failure. Int J Cardiol. 2016 Oct 15;221:841-6. doi: 10.1016/j.ijcard.2016.06.323. Epub 2016 Jul 1.

    PubMed 27434357
  • Amir O, Ben-Gal T, Weinstein JM, Schliamser J, Burkhoff D, Abbo A, Abraham WT. Evaluation of remote dielectric sensing (ReDS) technology-guided therapy for decreasing heart failure re-hospitalizations. Int J Cardiol. 2017 Aug 1;240:279-284. doi: 10.1016/j.ijcard.2017.02.120. Epub 2017 Mar 3.

    PubMed 28341372

Questions about this trial

What is this clinical trial studying?

A study testing Remote Dielectric Sensing (ReDS) Wearable System in people with Heart Failure, run by Sensible Medical Innovations Ltd. at 41 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 29 Dec 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 41 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early. Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The rate of recurrent events of HF readmissions (time frame: Entire follow-up period (Expected average of 6.5 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02448342, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Dec 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in